Colossal Biosciences is a pioneering genetic engineering company that leverages CRISPR and other advanced genomic tools to revive extinct species and safeguard critically endangered ones. Its flagship project involves bringing back the woolly mammoth, a keystone species whose reintroduction could help revitalize Arctic ecosystems. By combining scientific innovation with a deep commitment to environmental stewardship, Colossal seeks to restore biodiversity and strengthen ecological resilience worldwide. Ultimately, the company’s work serves as a rallying call for a new era in conservation — one in which humanity takes an active role in repairing and sustaining life on Earth.
Colossal Biosciences has raised $200 million in a Series C round from TWG Global, valuing the company at $10.2 billion. In total, the company has raised $435 million to date. “Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” said TWG Global CEO Mark Walter. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”
Colossal Biosciences, Dallas, Texas, United States, was founded in 2021 by Ben Lamm, Kent Wakeford, and Peter Phillips. In 2023, the company joined the unicorn club. Colossal Biosciences operates at the nexus of advanced biotechnology, wildlife conservation, climate-focused ecological solutions, and cutting-edge scientific research, positioning itself to drive innovation across multiple high-impact markets.
Share this post